Baseline characteristics
| Parameter . | Overall . | IVO + AZA/DEC . | VEN + AZA/DEC . | P value∗ . |
|---|---|---|---|---|
| Total (row percentages) | N = 280 | n = 181 | n = 99 | |
| Age at AML diagnosis, y | ||||
| Mean (SD) | 61.4 (14.19) | 60.4 (14.57) | 63.1 (13.35) | .1219 |
| Median (IQR) | 63 (53-72) | 61 (53-71) | 65 (55-75) | |
| (Min-Max) | (18-89) | (18-89) | (18-86) | |
| Age group, ≥65 y, n (%) | 120 (42.9) | 72 (39.8) | 48 (48.5) | .1593 |
| Sex, n (%) | ||||
| Male | 183 (65.4) | 123 (68.0) | 60 (60.6) | .2166 |
| Female | 97 (34.6) | 58 (32.0) | 39 (39.4) | |
| Race, n (%) | ||||
| White | 175 (62.5) | 118 (65.2) | 57 (57.6) | .0416† |
| Black | 46 (16.4) | 31 (17.1) | 15 (15.2) | |
| Asian | 38 (13.6) | 24 (13.3) | 14 (14.1) | |
| Native Hawaiian or Pacific Islander | 7 (2.5) | 2 (1.1) | 5 (5.1) | |
| American Indian or Alaska Native | 7 (2.5) | 1 (0.6) | 6 (6.1) | |
| Other | 1 (0.4) | 1 (0.6) | 0 (0.0) | |
| Unknown | 6 (2.1) | 4 (2.2) | 2 (2.0) | |
| Combination drug, n (%) | ||||
| AZA | 213 (76.1) | 142 (78.5) | 71 (71.7) | .2066 |
| DEC | 67 (23.9) | 39 (21.5) | 28 (28.3) | |
| Bone marrow blast level at diagnosis‡ | ||||
| Mean (SD) | 41.3 (18.47) | 40.5 (18.98) | 42.6 (17.5) | .1846 |
| Median (IQR) | 35 (28-52) | 35 (26-53) | 37 (30-50) | |
| (Min-Max) | (3-90) | (3-90) | (15-85) | |
| ECOG performance score, n (%) | ||||
| 0-1 | 214 (76.4) | 143 (79.0) | 71 (71.7) | .1695 |
| 2-4 | 66 (23.6) | 38 (21.0) | 28 (28.3) | |
| WHO classification, n (%) | ||||
| AML with RUNX1::RUNX1T1 | 21 (7.5) | 18 (9.9) | 3 (3.0) | .0357† |
| AML with CBFB::MYH11 fusion | 20 (7.1) | 16 (8.8) | 4 (4.0) | .1360 |
| AML with DEK::NUP214 fusion | 16 (5.7) | 11 (6.1) | 5 (5.1) | .7234 |
| AML with RBM15::MRTFA fusion | 19 (6.8) | 12 (6.6) | 7 (7.1) | .8885 |
| AML with BCR::ABL1 fusion | 12 (4.3) | 7 (3.9) | 5 (5.1) | .6403 |
| AML with KMT2A rearrangement | 12 (4.3) | 10 (5.5) | 2 (2.0) | .1663 |
| AML with MECOM rearrangement | 5 (1.8) | 5 (2.8) | 0 (0.0) | |
| AML with NUP98 rearrangement | 9 (3.2) | 7 (3.9) | 2 (2.0) | .4021 |
| AML with NPM1 mutation | 15 (5.4) | 10 (5.5) | 5 (5.1) | .8662 |
| AML with CEBPA mutation | 5 (1.8) | 4 (2.2) | 1 (1.0) | .4686 |
| AML with other defined genetic abnormalities | 37 (13.2) | 18 (9.9) | 19 (19.2) | .0289† |
| AML, myelodysplasia related | 47 (16.8) | 23 (12.7) | 24 (24.2) | .0135† |
| Unknown | 74 (26.4) | 49 (27.1) | 25 (25.3) | .7414 |
| IDH1 mutation type, n (%) | ||||
| R132C | 58 (20.7) | 39 (21.5) | 19 (19.2) | .6153 |
| R132G | 69 (24.6) | 41 (22.7) | 28 (28.3) | |
| R132H | 91 (32.5) | 63 (34.8) | 28 (28.3) | |
| R132L | 18 (6.4) | 13 (7.2) | 5 (5.1) | |
| R132S | 4 (1.4) | 2 (1.1) | 2 (2.0) | |
| Unknown | 40 (14.3) | 23 (12.7) | 17 (17.2) | |
| Transfusion dependence, n (%) | ||||
| Platelet transfusions | 108 (38.6) | 70 (38.7) | 38 (38.4) | .9620 |
| RBC transfusions | 168 (60.0) | 100 (55.2) | 68 (68.7) | .0282† |
| Parameter . | Overall . | IVO + AZA/DEC . | VEN + AZA/DEC . | P value∗ . |
|---|---|---|---|---|
| Total (row percentages) | N = 280 | n = 181 | n = 99 | |
| Age at AML diagnosis, y | ||||
| Mean (SD) | 61.4 (14.19) | 60.4 (14.57) | 63.1 (13.35) | .1219 |
| Median (IQR) | 63 (53-72) | 61 (53-71) | 65 (55-75) | |
| (Min-Max) | (18-89) | (18-89) | (18-86) | |
| Age group, ≥65 y, n (%) | 120 (42.9) | 72 (39.8) | 48 (48.5) | .1593 |
| Sex, n (%) | ||||
| Male | 183 (65.4) | 123 (68.0) | 60 (60.6) | .2166 |
| Female | 97 (34.6) | 58 (32.0) | 39 (39.4) | |
| Race, n (%) | ||||
| White | 175 (62.5) | 118 (65.2) | 57 (57.6) | .0416† |
| Black | 46 (16.4) | 31 (17.1) | 15 (15.2) | |
| Asian | 38 (13.6) | 24 (13.3) | 14 (14.1) | |
| Native Hawaiian or Pacific Islander | 7 (2.5) | 2 (1.1) | 5 (5.1) | |
| American Indian or Alaska Native | 7 (2.5) | 1 (0.6) | 6 (6.1) | |
| Other | 1 (0.4) | 1 (0.6) | 0 (0.0) | |
| Unknown | 6 (2.1) | 4 (2.2) | 2 (2.0) | |
| Combination drug, n (%) | ||||
| AZA | 213 (76.1) | 142 (78.5) | 71 (71.7) | .2066 |
| DEC | 67 (23.9) | 39 (21.5) | 28 (28.3) | |
| Bone marrow blast level at diagnosis‡ | ||||
| Mean (SD) | 41.3 (18.47) | 40.5 (18.98) | 42.6 (17.5) | .1846 |
| Median (IQR) | 35 (28-52) | 35 (26-53) | 37 (30-50) | |
| (Min-Max) | (3-90) | (3-90) | (15-85) | |
| ECOG performance score, n (%) | ||||
| 0-1 | 214 (76.4) | 143 (79.0) | 71 (71.7) | .1695 |
| 2-4 | 66 (23.6) | 38 (21.0) | 28 (28.3) | |
| WHO classification, n (%) | ||||
| AML with RUNX1::RUNX1T1 | 21 (7.5) | 18 (9.9) | 3 (3.0) | .0357† |
| AML with CBFB::MYH11 fusion | 20 (7.1) | 16 (8.8) | 4 (4.0) | .1360 |
| AML with DEK::NUP214 fusion | 16 (5.7) | 11 (6.1) | 5 (5.1) | .7234 |
| AML with RBM15::MRTFA fusion | 19 (6.8) | 12 (6.6) | 7 (7.1) | .8885 |
| AML with BCR::ABL1 fusion | 12 (4.3) | 7 (3.9) | 5 (5.1) | .6403 |
| AML with KMT2A rearrangement | 12 (4.3) | 10 (5.5) | 2 (2.0) | .1663 |
| AML with MECOM rearrangement | 5 (1.8) | 5 (2.8) | 0 (0.0) | |
| AML with NUP98 rearrangement | 9 (3.2) | 7 (3.9) | 2 (2.0) | .4021 |
| AML with NPM1 mutation | 15 (5.4) | 10 (5.5) | 5 (5.1) | .8662 |
| AML with CEBPA mutation | 5 (1.8) | 4 (2.2) | 1 (1.0) | .4686 |
| AML with other defined genetic abnormalities | 37 (13.2) | 18 (9.9) | 19 (19.2) | .0289† |
| AML, myelodysplasia related | 47 (16.8) | 23 (12.7) | 24 (24.2) | .0135† |
| Unknown | 74 (26.4) | 49 (27.1) | 25 (25.3) | .7414 |
| IDH1 mutation type, n (%) | ||||
| R132C | 58 (20.7) | 39 (21.5) | 19 (19.2) | .6153 |
| R132G | 69 (24.6) | 41 (22.7) | 28 (28.3) | |
| R132H | 91 (32.5) | 63 (34.8) | 28 (28.3) | |
| R132L | 18 (6.4) | 13 (7.2) | 5 (5.1) | |
| R132S | 4 (1.4) | 2 (1.1) | 2 (2.0) | |
| Unknown | 40 (14.3) | 23 (12.7) | 17 (17.2) | |
| Transfusion dependence, n (%) | ||||
| Platelet transfusions | 108 (38.6) | 70 (38.7) | 38 (38.4) | .9620 |
| RBC transfusions | 168 (60.0) | 100 (55.2) | 68 (68.7) | .0282† |
Data source was AML Chart Review latest update 25 June 2023. AML diagnosis identification period lasted from 1 November 2021 to 30 November 2022.
ECOG, Eastern Cooperative Oncology Group; IQR, interquartile range; Max, maximum; Min, minimum; RBC, red blood cell; SD, standard deviation; WHO, World Health Organization.
P value from a χ2 test for categorical variables; Mann-Whitney U of the means for continuous variables.
Indicates statistical significance.
One patient with bone morrow blast ≤3 was excluded from this metric.